prikaz prve stranice dokumenta Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma
  Preuzmi
PDF 723.44 KB
Znanstveni rad - Izvorni znanstveni rad
Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma
Clinical Genitourinary Cancer, 20 (2022), 5; e440-e452. https://doi.org/10.1016/j.clgc.2022.06.001
Makrakis, Dimitrios; Talukder, Rafee; Lin, Genevieve Ihsiu; Diamantopoulos, Leonidas N.; Dawsey, Scott; Gupta, Shilpa; Carril-Ajuria, Lucia; Castellano, Daniel; de Kouchkovsky, Ivan; Koshkin, Vadim S.; Park, Joseph J.; Alva, Ajjai; Bilen, Mehmet A.; Stewart, Tyler F.; McKay, Rana R.; Tripathi, Nishita; Agarwal, Neeraj; Vather-Wu, Naomi; Zakharia, Yousef; Morales-Barrera, Rafael; Devitt, Michael E.; Cortellini, Alessio; Fulgenzi, Claudia Angela Maria; Pinato, David J.; Nelson, Ariel; Hoimes, Christopher J.; Gupta, Kavita; Gartrell, Benjamin A.; Sankin, Alex; Tripathi, Abhishek; Zakopoulou, Roubini; Bamias, Aristotelis; Murgic, Jure; Fröbe, Ana; Rodriguez-Vida, Alejo; Drakaki, Alexandra; Liu, Sandy; Lu, Eric; Kumar, Vivek; Lorenzo, Giuseppe Di; Joshi, Monika; Isaacsson-Velho, Pedro; Buznego, Lucia Alonso; Duran, Ignacio; Moses, Marcus; Jang, Albert; Barata, Pedro; Sonpavde, Guru; Yu, Evan Y.; Montgomery, Robert Bruce; Grivas, Petros; Khaki, Ali Raza Više autora...

Citirajte ovaj rad

Makrakis, D., Talukder, R., Lin, G. I., Diamantopoulos, L. N., Dawsey, S., Gupta, S. ... Khaki, A. R. (2022). Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer, 20. (5), e440-e452. doi: 10.1016/j.clgc.2022.06.001

Makrakis, Dimitrios, et al. "Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma." Clinical Genitourinary Cancer, vol. 20, br. 5, 2022, str. e440-e452. https://doi.org/10.1016/j.clgc.2022.06.001

Makrakis, Dimitrios, Rafee Talukder, Genevieve Ihsiu Lin, Leonidas N. Diamantopoulos, Scott Dawsey, Shilpa Gupta, Lucia Carril Ajuria, et al. "Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma." Clinical Genitourinary Cancer 20, br. 5 (2022): e440-e452. https://doi.org/10.1016/j.clgc.2022.06.001

Makrakis, D., et al. (2022) 'Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma', Clinical Genitourinary Cancer, 20(5), str. e440-e452. doi: 10.1016/j.clgc.2022.06.001

Makrakis D, Talukder R, Lin GI, Diamantopoulos LN, Dawsey S, Gupta S, i sur.. Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer [Internet]. 10.2022. [pristupljeno 04.12.2024.];20(5):e440-e452. doi: 10.1016/j.clgc.2022.06.001

D. Makrakis, et al., "Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma", Clinical Genitourinary Cancer, vol. 20, br. 5, str. e440-e452, Listopad 2022. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:127:400491. [Citirano: 04.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:127:400491
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma
AutorDimitrios Makrakis
AutorRafee Talukder
AutorGenevieve Ihsiu Lin
AutorLeonidas N. Diamantopoulos
AutorScott Dawsey
AutorShilpa Gupta
AutorLucia Carril-Ajuria
AutorDaniel Castellano
AutorIvan de Kouchkovsky
AutorVadim S. Koshkin
AutorJoseph J. Park
AutorAjjai Alva
AutorMehmet A. Bilen
AutorTyler F. Stewart
AutorRana R. McKay
AutorNishita Tripathi
AutorNeeraj Agarwal
AutorNaomi Vather-Wu
AutorYousef Zakharia
AutorRafael Morales-Barrera
AutorMichael E. Devitt
AutorAlessio Cortellini
AutorClaudia Angela Maria Fulgenzi
AutorDavid J. Pinato
AutorAriel Nelson
AutorChristopher J. Hoimes
AutorKavita Gupta
AutorBenjamin A. Gartrell
AutorAlex Sankin
AutorAbhishek Tripathi
AutorRoubini Zakopoulou
AutorAristotelis Bamias
AutorJure Murgic
AutorAna Fröbe
AutorAlejo Rodriguez-Vida
AutorAlexandra Drakaki
AutorSandy Liu
AutorEric Lu
AutorVivek Kumar
AutorGiuseppe Di Lorenzo
AutorMonika Joshi
AutorPedro Isaacsson-Velho
AutorLucia Alonso Buznego
AutorIgnacio Duran
AutorMarcus Moses
AutorAlbert Jang
AutorPedro Barata
AutorGuru Sonpavde
AutorEvan Y. Yu
AutorRobert Bruce Montgomery
AutorPetros Grivas
AutorAli Raza Khaki
Autorova ustanova(Klinički bolnički centar Sestre milosrdnice)
Autorova ustanovaSveučilište u Zagrebu
Stomatološki fakultet
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
Background: Sites of metastasis have prognostic significance in advanced urothelial carcinoma (aUC), but more information is needed regarding outcomes based on metastatic sites in patients treated with immune checkpoint inhibitors (ICI). We hypothesized that presence of liver/bone metastases would be associated with worse outcomes with ICI. Methods: We identified a retrospective cohort of patients with aUC across 26 institutions, collecting demographics, clinicopathological, treatment, and outcomes information. Outcomes were compared with logistic (observed response rate; ORR) and Cox (progression-free survival; PFS, overall survival; OS) regression between patients with/without metastasis beyond lymph nodes (LN) and those with/without bone/liver/lung metastasis. Analysis was stratified by 1st or 2nd+ line. Results: We identified 917 ICI-treated patients: in the 1st line, bone/liver metastases were associated with shorter PFS (HR: 1.65 and 2.54), OS (HR: 1.60 and 2.35, respectively) and lower ORR (OR: 0.48 and 0.31). In the 2nd+ line, bone/liver metastases were associated with shorter PFS (HR: 1.71 and 1.62), OS (HR: 1.76 and 1.56) and, for bone-only metastases, lower ORR (OR: 0.29). In the 1st line, LN-confined metastasis was associated with longer PFS (HR: 0.53), OS (HR:0.49) and higher ORR (OR: 2.97). In the 2 nd+ line, LN-confined metastasis was associated with longer PFS (HR: 0.47), OS (HR: 0.54), and higher ORR (OR: 2.79); all associations were significant. Conclusion: Bone and/or liver metastases were associated with worse, while LN-confined metastases were associated with better outcomes in patients with aUC receiving ICI. These findings in a large population treated outside clinical trials corroborate data from trial subset analyses.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaClinical Genitourinary Cancer
Brojčani podacivol. 20, br. 5, str. e440-e452
p-ISSN1558-7673
DOIhttps://doi.org/10.1016/j.clgc.2022.06.001
URN:NBNurn:nbn:hr:127:400491
Datum objave publikacije2022-10
URL dokumentahttps://linkinghub.elsevier.com/retrieve/pii/S1558767322001252
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-10-22 07:12:48